P-046 - WITHDRAWN - LRRK2 INHIBITION BY BIIB122/DNL151 SUPPORTS EXPOSURES ACHIEVING ROBUST TARGET AND LYSOSOMAL ENGAGEMENT IN PARKINSON’S PATIENTS: A TRANSLATIONAL PK-PD APPROACH.
H. Wong, B. Wong, S. Huntwork-Rodriguez, H. Solanoy, D. Diaz, A. Kay, M. Troyer, D. Jennings, V. Daryani; Denali Therapeutics Inc., South San Francisco, CA, USA.
.png)